23 October 2020: Original Paper
Transplant Radical Nephrectomy and Transplant Radical Nephroureterectomy for Renal Cancer: Postoperative and Survival Outcomes
Reza Nabavizadeh 1ABCDEF , Anika A. Noorali 2ABCDEF , Salima S. Makhani 2ABCDEF , Gordon Hong 3ABC , Sarah Holzman 4CDE , Dattatraya H. Patil 1CDE , Frances Y. Kim 1BCF , Paul L. Tso 5ADE , Nicole A. Turgeon 6DEF , Kenneth Ogan 17ADEF , Viraj A. Master 17ADEF*DOI: 10.12659/AOT.925865
Ann Transplant 2020; 25:e925865
Table 5 Literature review of renal allograft RCC treated by transplant radical nephrectomy.
| First Author | No. of transplant recipients | No. with allograft cancer (n,%) | Total treated by TRN (n) | Age at tumor diagnosis; sex | Primary kidney disease (n) | Average time from transplant to diagnosis (years) |
|---|---|---|---|---|---|---|
| Guleryuz []* | 46,145 | 116 (0.25%) | 30 | 51.4 (mean); N/A | N/A | 8.83 |
| Tillou []* | 41, 806 | 79 (0.19%) | 38 | N/A | N/A | N/A |
| Troxell []17 | 4,200 | 12 (0.29%) | 5 | 48.5; 3 M, 1 F | N/A | 16 |
| 9; M | N/A | 9 | ||||
| Su []20 | 1,241 | 4 (0.32%) | 1 | 28; F | ADMCD | 0.75 |
| Vegso []21 | 3,530 | 9 (0.25%) | 4 | 45.3 (mean); N/A | N/A | 10.97 |
| Swords []15 | 804 | 4 (0.50%) | 2 | 51 (mean); 2 M | FSG, diabetic nephropathy | 16 |
| Ploussard []33 | 2,396 | 17 (0.71%) | 4 | 51.8 (mean); 2 M, 2 F | IN (2); PCKD (1); Unknown (1) | 9.3 |
| Leveridge []35 | 3,568 | 71 (1.99%) | 8 | 48.2 (mean) | N/A | 12.1 |
| Barama []5 | 1,073 | 5 (0.47%) | 1 | 43; F | Diabetic nephropathy | 11 |
| ** | ||||||
| Guleryuz []* | Presenting symptoms (6) | 0.1–1.0 (range), clear cell (19) | N/A | Only functional kidneys were included in this study. UCC was excluded. | 24 mo (IQR 4.1–76.6); hematoma (2); deceased (3) | |
| Tillou []* | Incidental finding (30) | N/A | N/A | Functional (23) | 45.4 mo (mean) (IQR 0.7–164.2) | |
| Troxell []17 | N/A | 1.6–5.0 (range); Papillary clear cell (3) | N/A | Non-functional | 12–84 mo (range); alive (3); deceased (1) | |
| N/A | 2.3; Biphasic papillary | N/A | Partial nephrectomy failure at 4 months prompted an allograft nephrectomy | Alive- 96 mo | ||
| Su []20 | New onset hematuria | 4.0×6.0, Clear cell RCC | Mid to lower pole | Functional (Cr of 1.81 mg/dL) | Alive- 98 mo | |
| Vegso []21 | N/A | |||||
| Swords []15 | Incidental (1) | 1.5–2.3 (range); Papillary RCC Type 1 (2) | N/A | Non-functional | Alive- 24 mo | |
| Ploussard []33 | N/A | 1.0–5.0 (range); Papillary RCC (2); Clear cell RCC (2) | Medio-renal (1), Lower pole (2); Med/lower pole (1) | Unspecified (4) | Alive- 28–96 mo (4) | |
| Leveridge []35 | N/A | Papillary (5); Clear cell (3) | N/A | N/A | Alive- 3.6 years (7); deceased (1) | |
| Barama []5 | Incidental | 2.5×3.4 unspecified RCC | Upper pole | Functional (Cr of 2.03 mg/dL) | Alive- 6 mo | |
| Alharbi [], Althaf [], Pandya [], Banshodani [], Asciak [], Ajabnoor [], Greco []26 | – | 7 case reports | 7 | 13.5–56 (range); 4 M, 3 F | IC-MPGN (1); Unknown (4); Other (2) | 5–20 (range) |
| ** | ||||||
| Alharbi [], Althaf [], Pandya [], Banshodani [], Asciak [], Ajabnoor [], Greco []26 | GI symptoms (3); gross hematuria (2); incidental (2); weight loss (1); UTI (1) | 1.3–9.0; Chromophobe RCC (4);Clear cell RCC (2);Papillary RCC (1) | Mid renal (2); Upper pole (1); Lower pole (2); Other (2) | Non-functional (5); Functional (2) (Cr of 1.0 mg/dL) | Alive- 2.5–55 mo (4);Not available (3) | |
| mo – months; UTUC – upper tract urothelial cancer; RCC – renal cell carcinoma; Cr – creatinine; US – ultrasound; CT – computerized tomography; MRI – magnetic resonance imaging; N/A – not available; IN – interstitial nephropathy; ADMCD – autosomal dominant medullary cystic disease; PCKD – polycystic kidney disease; FSG – focal segmental glomerulosclerosis; IC-MPGN – immune-mediated membranoproliferative glomerulo-nephropathy. Gastrointestinal (GI) symptoms: Abdominal pain, nausea, vomiting, diarrhea. * National, multicenter study; ** tumor size detected by imaging. | ||||||